Related Experiment Video

Updated: Aug 20, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with

Masayuki Kobayashi1, Noboru Machida, Megumi Mitsuishi

  • 1Department of Veterinary Surgery, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan. masa-k@cc.tuat.ac.jp

American Journal of Hypertension
|December 21, 2004
PubMed

Insights

Metoprolol (MP) treatment improved survival and prevented diastolic dysfunction progression in rats with diastolic heart failure (DHF). This suggests MP may offer clinical benefits for hypertension-induced DHF.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Chronic beta-blocker therapy is established for systolic heart failure but its role in diastolic heart failure (DHF) is unclear.
  • Diastolic heart failure (DHF) is characterized by preserved left ventricular (LV) systolic function but impaired diastolic filling.

Purpose of the Study:

  • To investigate the efficacy of metoprolol (MP) in preventing and treating DHF in a rat model.
  • To evaluate the effects of MP on LV function, remodeling, fibrosis, and survival in DHF.

Main Methods:

  • Dahl salt-sensitive hypertensive rats on a high-salt diet were treated with metoprolol (MP) either early (7 weeks) or late (17 weeks).
  • Left ventricular (LV) function and remodeling were assessed using echocardiography, hemodynamics, and pathology.

Main Results:

  • Metoprolol (MP) significantly attenuated LV hypertrophy and prevented the progression of diastolic dysfunction and myocardial fibrosis in DHF rats.
  • Early and late MP treatment markedly improved survival rates in DHF rats compared to untreated controls.

Conclusions:

  • Metoprolol (MP) effectively prevents LV hypertrophy development and diastolic dysfunction progression, improving survival in DHF.
  • MP's preventive effect on myocardial fibrosis is a key mechanism for halting diastolic dysfunction, suggesting potential clinical benefits for hypertension-related DHF.
Abstract

More Related Videos

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...